1. Home
  2. NVO vs PM Comparison

NVO vs PM Comparison

Compare NVO & PM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVO
  • PM
  • Stock Information
  • Founded
  • NVO 1923
  • PM 1987
  • Country
  • NVO Denmark
  • PM United States
  • Employees
  • NVO N/A
  • PM N/A
  • Industry
  • NVO Biotechnology: Biological Products (No Diagnostic Substances)
  • PM Medicinal Chemicals and Botanical Products
  • Sector
  • NVO Health Care
  • PM Health Care
  • Exchange
  • NVO Nasdaq
  • PM Nasdaq
  • Market Cap
  • NVO 278.0B
  • PM 277.4B
  • IPO Year
  • NVO N/A
  • PM N/A
  • Fundamental
  • Price
  • NVO $71.49
  • PM $180.52
  • Analyst Decision
  • NVO Strong Buy
  • PM Strong Buy
  • Analyst Count
  • NVO 4
  • PM 12
  • Target Price
  • NVO $128.00
  • PM $159.58
  • AVG Volume (30 Days)
  • NVO 11.1M
  • PM 5.4M
  • Earning Date
  • NVO 05-07-2025
  • PM 07-22-2025
  • Dividend Yield
  • NVO 2.25%
  • PM 2.99%
  • EPS Growth
  • NVO 17.93
  • PM N/A
  • EPS
  • NVO 3.40
  • PM 4.86
  • Revenue
  • NVO $43,922,211,349.00
  • PM $38,386,000,000.00
  • Revenue This Year
  • NVO $18.59
  • PM $11.90
  • Revenue Next Year
  • NVO $15.61
  • PM $8.31
  • P/E Ratio
  • NVO $20.13
  • PM $37.16
  • Revenue Growth
  • NVO 24.11
  • PM 6.78
  • 52 Week Low
  • NVO $57.00
  • PM $98.93
  • 52 Week High
  • NVO $148.15
  • PM $181.36
  • Technical
  • Relative Strength Index (RSI)
  • NVO 59.49
  • PM 69.99
  • Support Level
  • NVO $68.30
  • PM $174.93
  • Resistance Level
  • NVO $71.30
  • PM $179.83
  • Average True Range (ATR)
  • NVO 1.96
  • PM 2.78
  • MACD
  • NVO 0.60
  • PM 0.45
  • Stochastic Oscillator
  • NVO 99.17
  • PM 95.58

About NVO Novo Nordisk A/S

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About PM Philip Morris International Inc

Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heatsticks, vapes, and oral nicotine offerings primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI has not only diversified away from smokeable products but also gained a toehold into the US to sell its iQOS heated tobacco product.

Share on Social Networks: